| Bioactivity | GSK163929 (compound 122) is an orally active, anti-HIV CCR5 antagonist with low inhibitory potency against hEGR. GSK163929 had no adverse effects in rats at 2000 mg/kg/day (i.v., 7 d) and in dogs at 250 mg/kg/day (i.v., 7 d)[1]. |
| CAS | 716354-04-0 |
| Formula | C36H40ClF2N5O3S |
| Molar Mass | 696.25 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kazmierski WM, et al. Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. J Med Chem. 2011 Jun 9;54(11):3756-67. |
GSK163929
CAS: 716354-04-0 F: C36H40ClF2N5O3S W: 696.25
GSK163929 (compound 122) is an orally active, anti-HIV CCR5 antagonist with low inhibitory potency against hEGR. GSK1639
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.